Shona Dalal

You are already at the latest version Eastern and Southern Africa (ESA) carries the world's heaviest combined burden of HIV and cervical cancer. People living with HIV (PLHIV) face higher HPV acquisition, reduced clearance, and accelerated progression to cervical cancer; WHO recommends a two- or three-dose HPV vaccination schedule for this group regardless of age or antiretroviral therapy (ART) status.

Introduction Cervical cancer, a preventable and treatable malignancy, is the fourth most commonly detected cancer in women, with an estimated 660 000 women diagnosed worldwide and 350 000 dying from the disease in 2022.1 In low-income and middle-income countries (LMICs), cases are often diagnosed late and associated with higher mortality than in high-income countries; one-fifth of deaths occur in sub-Saharan Africa.2 Women living with HIV have a six-times higher risk of cervical cancer than...

1. Hare CB Coll J Ruane P et al. The phase 3 discover study: daily F/TAF or F/TDF for HIV pre-exposure prophylaxis. CROI, Seattle, WA, USAMarch 4–7, 2019 2. Baeten J Donnell D Ndase P et al. Single-agent TDF versus combination FTC/TDF PrEP among heterosexual men and women. CROI, Boston, MA, USAMarch 3–6, 2014 3. Molina JM Capitant C Spire B et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med. 2015; 373: 2237-2246 4. Grant RM Lama JR Anderson PL et al.